JATT Acquisition Corp. (NYSE: JATT) is a Special Purpose Acquisition Company (“SPAC”), with a focus on the Life Sciences sector
Intersection of AI and mechanistic genetics
Therapeutic areas of interest; immunology, oncology, rare disease
With attractive and promising clinical stage assets that target unmet medical needs and are near an inflection point in value creation.
JATT has repeated success in realizing value inflection points from early R+D through commercialization to meet unmet medical needs
JATT has global experts in identifying high-value assets with an exceptional proprietary international network
JATT possesses a deep understanding of identifying assets that are well-received in private and public markets and in helping assets into public markets
JATT has a track-record of profitable deal-making and successfully executing M&A, partnership deals, cross-over rounds and public market deals.
JATT has a team that has a strong track record in delivering value and generating ROI for investors
Dr. Someit Sidhu
Founder, CEO & Director
Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics
Tauhid Ali ,PhD
COO & Director
Former EVP at Cambrian Biopharma and Head of Rare Disease Strategy & Founder of TAKcelerator™ at Takeda
Verender S. Badial
CFO
Former MD in ECM at Société Générale and ABN AMRO Rothschild
Founder of Cryfield Investments
Graeme Sloan
General Counsel
Former Global Co-Head of M&A at Morrison & Foerster LLP, former global Co-Chair of M&A at Latham & Watkins LLP, Co-Chair of Lex Mundi cross border transaction group
Arnout Ploos van Amstel
Director
Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis
Javier Cote‐Sierra, PhD
Director
Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme
Yuan-Hua Ding, PhD
Advisor
Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs
Founder, CEO & Director
Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics
COO & Director
Former EVP at Cambrian Biopharma and Head of Rare Disease Strategy & Founder of TAKcelerator™ at Takeda
CFO
Former MD in ECM at Société Générale and ABN AMRO Rothschild
Founder of Cryfield Investments
General Counsel
Former Global Co-Head of M&A at Morrison & Foerster LLP, former global Co-Chair of M&A at Latham & Watkins LLP, Co-Chair of Lex Mundi cross border transaction group
Director
Head of Crossover and Quantitative Equity at Athanor Capital and Former COO of Global Private Investing at D.E. Shaw & Co
Director
Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis
Director
Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme
Advisor
Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs
.